Neoadjuvant Pegylated Lipsomal Doxorubicin/Cyclophosphamide Plus Trastuzumab/Pertuzumab Yields Promising Efficacy in HER2+ Breast Cancer

Article

Findings from a phase 2 clinical study indicated that neoadjuvant pegylated liposomal doxorubicin plus cyclophosphamide, trastuzumab, and pertuzumab demonstrated promising efficacy and safety in the treatment of HER2-positive breast cancer.

Treatment with a neoadjuvant combination of pegylated liposomal doxorubicin plus cyclophosphamide, trastuzumab (Herceptin), pertuzumab (Perjeta), and a taxane could be a safe and effective treatment option for patients with HER2-positive breast cancer, according to preliminary results from a single-arm phase 2 study that were presented at the 2022 European Society for Medical Oncology (ESMO) Congress.


Among patients who received the combination, the pathologic complete response (pCR) rate was 59.4% (n = 38/64). Moreover, the overall response rate (ORR) after the first four cycles of treatment was 68.8%.

In this trial, a total of 78 patients enrolled, of whom 64 had pathological results. Eligible patients had been diagnosed with non-metastatic HER2-positive breast cancer and needed to have a tumor measuring 2 cm or greater or have positive lymph nodes. Patients also needed to have a left ventricular ejection fraction (LVEF) of 55% or more.

Neoadjuvant treatment consisted of pegylated liposomal doxorubicin at a dose of 30 to 35 mg/m2 plus cyclophosphamide, trastuzumab, and pertuzumab every 3 weeks for 4 cvcles followed by a taxane and trastuzumab plus pertuzumab for an additional 4 cvcles.

The primary end point was pCR rate, and ORR after the first 4 cycles of treatment served as the secondary end point.

In total, 29.7% of patients were aged 40 years and younger and 70.3% were over 40 years of age. Over half of all patients had hormone receptor (HR)–positive disease (54.7%). In total, 62.5% of patients had T1 to T2 tumor staging and 37.5% were T3 to T4. Most patients had at least 1 positive lymph node (62.5%) and the majority had stage II disease (71.9%).

In a subgroup analysis, patients aged 40 years or younger experienced a pCR rate of 42.1%, and those who were older than 40 had a pCR of 66.7%. Patients whose disease was HR negative, the pCR rate was 65.5% (19/29) compared with 54.3% in the HR-positive population. In patients with T1 to T2 tumor staging, the pCR rate was 57.5% vs 62.5% among those with T3 to T4 staging. Moreover, those who were lymph node–negative experienced a pCR rate of 70.6% vs 55.3% in the lymph node–positive group. Additionally, patients with clinical stage II disease experienced a pCR rate of 56.5%, and for those with stage III disease, the rate was 66.7%.

In terms of safety, the most common grade 3/4 adverse effects (AEs) included white blood cell count decrease (21.9%), lymphocyte count decrease (21.9%), and neutrophil count decrease (18.8%). Additionally, 6 patients experienced asymptomatic LVEF decline by 10% or more from baseline; notably, all LVEFs were above 55%.


Reference


Yang Y, Jin L, Rao N, et al. 192P: A phase I single-arm clinical study of neoadjuvant treatment with pegylated liposomal doxorubicin (PLD) plus cvclophosphamide (C) combined with trastuzumab (H) and pertuzumab (P) in HER2-positive (HER2+) breast cancer (BC). Ann Oncol. 2022;33(suppl 7):S55-S84. doi:10.1016/annonc/annonc1038

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Related Content